✦ LIBER ✦

Alternating tamoxifen and medroxyprogesterone acetate in postmenopausal advanced breast cancer patients — short and long term endocrine effects

✍ Scribed by Luciano Canobbio; Enzo Galligioni; Giampietro Gasparini; Tiziana Fassio; Diana Crivellari; Danilo Villalta; Gianfranco Santini; Silvio Monfardini; Francesco Boccardo

Book ID: 105317151
Publisher: Springer US
Year: 1987
Tongue: English
Weight: 400 KB
Volume: 10
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01810584

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral high-dose medroxyprogesterone aceta

Oral high-dose medroxyprogesterone acetate versus tamoxifen: A randomized crossover trial in postmenopausal patients with advanced breast cancer

✍ Hendrik Van Veelen; Pax H. B. Willemse; Tonnis Tjabbes; Marjan J. H. Schweitzer; 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

Influence of aminoglutethimide on the me

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

✍ S. Lundgren; P. E. Lønning; A. Aakvaag; S. Kvinnsland 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 496 KB

The effects of low and high dose medroxy

The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients

✍ Dowsett, M; Lal, Anshumala; Smith, IE; Jeffcoate, SL 📂 Article 📅 1987 🏛 Nature Publishing Group 🌐 English ⚖ 631 KB

Plasma insulin-like growth factor I and

Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen

✍ Eija I. Lahti; Mikael Knip; Timo J. Laatikainen 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 629 KB

Background. Insulin-like growth factor I (IGF-I) is a potent mitogen for breast cancer cells. The majority of IGF-I in plasma is bound to IGF binding proteins (IGFBPs), which modulate the biologic effects of IGF-I. Methods. Plasma concentrations of IGF-I, IGFBP-I, and IGFBP-3 were compared between

Second and third line hormonotherapy in

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

✍ E. Garcia-Giralt; Y. Ayme; M. Carton; A. Daban; T. Delozier; P. Fargeot; P. Fumo 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 602 KB

The effect of endocrine therapy with med

The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer

✍ M. J. Reed; A. Christodoulides; R. Koistinen; M. Seppälä; J. D. Teale; M. W. Ghi 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 413 KB 👁 2 views